Search Results

U.S. and Chinese flags in concrete, broken in the middle

BIOSECURE Act

WuXi Mulls Sale of Some US, European Operations: FT

The Financial Times reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe.

October 3, 2024

·

2 min read

·

Tristan Manalac

United States and China flag together realtions textile cloth fabric texture

BIOSECURE Act

WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow

WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.

October 8, 2024

·

5 min read

·

Ben Hargreaves

Podcast

BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More

Cell and gene therapy investment rebounds; WuXi Biologics and other companies named in BIOSECURE Act mull options; Bayer, J&J and Pfizer’s recent layoffs; updates from the weight loss space.

October 9, 2024

·

1 min read

·

Heather McKenzie

Downward trendline superimposed on a picture of a man working on financial records

China

WuXi Biologics Takes Net Profit Hit Despite Inking Record Number of New Projects

With the potential passage of the BIOSECURE Act looming, WuXi Biologics reported a 24% drop in net profit in the first half of 2024.

August 22, 2024

·

2 min read

·

Tristan Manalac

Biopharma items with cyber accents/Taylor Tieden for BioSpace

Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs

As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.

July 3, 2024

·

4 min read

·

Tyler Patchen

Pictured: Collage of a dragon, congress, and money

BIOSECURE Act

WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms

With the BIOSECURE Act likely to be voted on in Congress this year, WuXi AppTec’s U.S. revenue dropped 1.2% in the first half of 2024 while the Chinese company increased its lobbying efforts.

July 29, 2024

·

2 min read

·

Tyler Patchen

Pictured: Biopharma items with cyber accents

Policy

Scrutiny of WuXi Raises Potential Opportunities for Indian CDMOs

As congressional pressure increases on WuXi AppTec and other China-based companies over alleged ties to the Chinese government, India’s contract development and manufacturing organization sector could benefit.

June 25, 2024

·

6 min read

·

Tyler Patchen

Press Releases

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

October 30, 2024

·

2 min read

Earnings

WuXi AppTec Remains Resilient Amid Threat from BIOSECURE Act, Continues to Attract New Clients

As the Chinese contract manufacturer awaits the U.S. Senate’s consideration of the BIOSECURE Act, it has added 800 new customers in the first nine months of 2024, while being hit with a 2% revenue decline in the third quarter.

October 29, 2024

·

2 min read

·

Tristan Manalac

Business

WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations

WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, announced its financial results for the first quarter ending March 31, 2024.

April 29, 2024

·

18 min read